IP Library › Granted Patent US 12,467,103
Granted Patent B2
US 12,467,103 · App. 17/813,467 · Granted Nov 11, 2025

Ligase fusion proteins and application thereof

Inventors: Gang Qin (Suzhou, CN); Cao Lv (Suzhou, CN); Joachim Walter (Mittelbiberach, DE); Rolf Werner (Biberach an der Riss, DE); Yunpeng Zhong (Suzhou, CN)
Assignee: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
A61K47/6801A61K47/60A61K47/68033A61K47/6817C12N9/52C12N11/06C12Y304/2207C07K2319/61
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,467,103
App. No.
17/813,467
Granted
Nov 11, 2025
Kind
B2
Abstract

The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit.

Claims (17)

1 . An immobilized ligase, comprising a ligase fusion protein immobilized to a support, wherein the ligase fusion protein consists of a ligase, a mutant haloalkane dehalogenase or a variant thereof comprising the amino acid sequence of SEQ ID NO: 28 or an amino acid sequence having a sequence identity of at least 95% thereto, and optionally a linker peptide, wherein the ligase, the mutant haloalkane dehalogenase or the variant thereof, and optionally the linker peptide are fused by a covalent bond, wherein the ligase has an isoelectric point (pI) of about 7.5 to about 10.0,

the mutant haloalkane dehalogenase or the variant thereof has an isoelectric point of about 4.5 to about 5.0, and

the pI of the ligase fusion protein is about 2.0 to about 4.5 pH units lower than that of the ligase, wherein the ligase is a sortase, and wherein the support comprises a haloalkyl linker such that the ligase fusion protein is immobilized on the support through covalent interaction between the haloalkyl linker and the mutant haloalkane dehalogenase or the variant thereof.

2 . The immobilized ligase according to claim 1 , wherein the haloalkyl linker is a chloroalkane linker produced by a chloroalkyl substrate having the structure of formula (I-1):

wherein u is an integer of 1 to 20, v is an integer of 0 to 20, and w is an integer of 1 to 19.

3 . The immobilized ligase according to claim 2 , wherein the support has the structure of formula (II):

wherein u is an integer of 1 to 20, v is an integer of 0 to 20, and w is an integer of 1 to 19; is a resin, a bead, a membrane, a gel, a matrix, a film, a plate, a well, a tube, a glass slide or a surface.

4 . The immobilized ligase according to claim 1 , wherein the ligase is a sortase A.

5 . The immobilized ligase according to claim 4 , wherein the sortase A comprises a modified amino acid sequence selected from the group consisting of SEQ ID NOs: 1-26 or an amino acid sequence having a sequence identity of at least 95% thereto, and wherein the modification comprises amino acid substitutions selected from SNAT (Ser, Asn, Ala, Thr), YNAT (Tyr, Asn, Ala, Thr), WNDT (Trp, Asn, Asp, Thr) and VNNS (Val, Asn, Asn, Ser) at positions 34, 100, 105 and 136.

6 . The immobilized ligase according to claim 5 , wherein the sortase A comprises the amino acid sequence of SEQ ID NO: 27 or an amino acid sequence having a sequence identity of at least 95% thereto.

7 . The immobilized ligase according to claim 3 , wherein

is a resin.

8 . The immobilized ligase according to claim 7 , wherein the resin is an agarose resin, a silicone resin, a polymethyl methacrylate resin or cellulose resin.

9 . The immobilized ligase according to claim 8 , wherein the resin is a highly crosslinked agarose resin.

10 . The immobilized ligase according to claim 1 , wherein the pI of the ligase fusion protein is about 4.5 to about 6.5.

11 . The immobilized ligase according to claim 1 , wherein the pI of the ligase fusion protein is about 5.0 to about 6.0.

12 . The immobilized ligase according to claim 1 , wherein the ligase fusion protein has the amino acid sequence of SEQ ID NO: 29.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2022
From: QIN, GANG; LV, CAO; WALTER, JOACHIM; WERNER, ROLF; ZHONG, YUNPENG
To: GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.
Reel/Frame 061136/0131 →
Priority Claims (1)
WO PCT/CN2021/074082 · Jan 28, 2021 · international
Continuity (2)
Division 17374262 · Jul 13, 2021
Related Publication 20220403360A1 · Dec 22, 2022
References Cited (64)
US 7238489B2 · Schneewind et al. · 2007 [cited by applicant]
US 7429472B2 · Darzins et al. · 2008 [cited by applicant]
US 7888086B2 · Darzins et al. · 2011 [cited by applicant]
US 8202700B2 · Darzins et al. · 2012 [cited by applicant]
US 8420367B2 · Darzins · 2013 [cited by examiner]
US 11453870B2 · Qin et al. · 2022 [cited by applicant]
US 20060024808A1 · Darzins et al. · 2006 [cited by applicant]
US 20060229253A1 · Doronina et al. · 2006 [cited by applicant]
US 20110321183A1 · Ploegh et al. · 2011 [cited by applicant]
US 20140120035A1 · Govindan et al. · 2014 [cited by applicant]
US 20160032346A1 · Tsourkas et al. · 2016 [cited by applicant]
US 20160193355A1 · Qin et al. · 2016 [cited by applicant]
US 20160297890A1 · Agatsuma et al. · 2016 [cited by applicant]
US 20170112944A1 · Qin et al. · 2017 [cited by applicant]
US 20200277403A1 · Tsourkas et al. · 2020 [cited by applicant]
US 20210187114A1 · Qin et al. · 2021 [cited by applicant]
CN 106237341 · 2016 [cited by applicant]
EP 3647419A1 · 2020 [cited by applicant]
WO WO2004072232 · 2004 [cited by applicant]
WO WO2005054821 · 2005 [cited by applicant]
WO WO2006093529 · 2006 [cited by applicant]
WO WO2008054821 · 2008 [cited by applicant]
WO WO2010086439A1 · 2010 [cited by applicant]
WO WO2014140317 · 2014 [cited by applicant]
WO WO2014177042 · 2014 [cited by applicant]
WO WO2014183066 · 2014 [cited by applicant]
WO WO2015127365A2 · 2015 [cited by examiner]
WO WO2015165413 · 2015 [cited by applicant]
WO WO2016014501 · 2016 [cited by applicant]
WO WO2017167712A1 · 2017 [cited by applicant]
WO WO2020072764A1 · 2020 [cited by applicant]
Sun et al (PeerJ. Jun. 25, 2015;3:e1060, p. 1-24) (Year: 2015). [cited by examiner]
Los et al (ACS Chem. Biol. 2008, 3, 6, 373-382) (Year: 2008). [cited by examiner]
Roux et al (J Cell Biol (2012) 196 (6): 801-810) (Year: 2012). [cited by examiner]
Warden-Rothman et al (Anal Chem. Nov. 19, 2013;85(22):11090-7) (Year: 2013). [cited by examiner]
The Protein Man (“Which agarose (sepharose) to choose? 2, 4 or 6%?”; https://info.gbiosciences.com/blog/bid/202307/which-agarose-sepharose-to-choose-2-4-or-6-crosslinked#:˜:text=Crosslinked%20agarose%20is%20resistant%20… [cited by examiner]
Miyao et al (Analytical Biochemistry 484 (2015) 113-121) (Year: 2015). [cited by examiner]
Ljungquist et al (Eur. J. Biochem 186, 563-569 (1989)) (Year: 1989). [cited by examiner]
Suliman (“Identifying sortase A variants with higher catalytic activity” thesis dissertation. Available online Jul. 5, 2014, retrieved Apr. 10, 2024 from https://scholarscompass.vcu.edu/etd/383/?utm_source=scholarscompa… [cited by examiner]
Antos et al (Curr Protoc Protein Sci. Aug. 1, 2017;89:15.3.1-15.3.19) (Year: 2017). [cited by examiner]
Glasgow et al (J Am Chem Soc. Jun. 22, 2016;138(24):7496-9) (Year: 2016). [cited by examiner]
Witte, M., Wu, T., Guimaraes, C et al. Site-specific protein modification using immobilized sortase in batch and continuous-flow systems. Nat Protoc 10, 508-516 (2015) (Year: 2015). [cited by examiner]
Warden-Rothman et al (Sortase-tag expressed protein ligation: combining protein purification and site-specific bioconjugation into a single step. Anal Chem. Nov. 19, 2013;85(22):11090-7) (Year: 2013). [cited by examiner]
Wen (Discovery and investigation of O-xylosylation in engineered proteins containing a (GGGGS)n linker. Anal Chem. May 7, 2013; 85(9):4805-12) (Year: 2013). [cited by examiner]
Guimaraes, C et al., “Site-specific C-terminal and Internal Loop Labeling of Proteins Using Sortase-mediated Reactions,” Nature Protocols, 2013, 8 (9), 1787-1799. [cited by applicant]
Hirakawa, H et al., “Artificial Protein Complexes for Biocatalysis,” Topics in Catalysis, 2012, 55, 1124-1137. [cited by applicant]
Hoelzel, C. et al., “Visualizing and Manipulating Biological Processes Using HaloTag and SNAP-Tag Technologies,” HHS Public Access, Author Manuscript, available in PMC 2020, 31 pages, face of article states: Published i… [cited by applicant]
Ke, N. et al., “Visualization of Periplasmic and Cytoplasmic Proteins with a Self-labeling Protein Tag,” Journal of Bacteriology, 2016, 198 (7), 1035-1043. [cited by applicant]
Li, A. et al., “Research Progress of Microbial Haloalkane Dehalogenase—A Review,” Wei Sheng Wu Xue Bao (Acta Microbiologica Sinica), 2015, 55 (4), 381-388, Abstract only. [cited by applicant]
Buldun, C et al., “SnoopLigase Catalyzes Peptide-Peptide Locking and Enables Solid-Phase Conjugate Isolation,” Journal of American Chemical Society, vol. 140, No. 8, pp. 3008-3018, (2018). [cited by applicant]
Ottis, P. et al., “Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation,” ACS Chem Biol., vol. 12, No. 10, pp. 2570-2578, (2017). [cited by applicant]
Pei, H. et al., “Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery,” RSC Adv., vol. 9, No. 30, pp. 16967-16976, (2019). [cited by applicant]
Beerli, et al., “Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency”, [cited by applicant]
Bradshaw, et al., “Molecular Features of the Sortase Enzyme Family”, [cited by applicant]
Carillo, et al., “The Multiple Sequence Alignment Problem in Biology”, [cited by applicant]
Dramsi, et al., “Sorting Sortases: a Nomenclature Proposal for the Various Sortases of Gram-Positive Bacteria”, [cited by applicant]
Fernandez-Suarez, et al., “Protein-Protein Interaction Detection in Vitro and in Cells by Proximity Biotinylation”, vol. 130, No. 29, pp. 9251-9253, (2008). [cited by applicant]
Gao, et al., “Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs)”, [cited by applicant]
Hay, et al., “In vivo polyester immobilized sortase for tagless protein purification”, [cited by applicant]
Malik, et al., “A Comprehensive in Silico Analysis of Sortase Superfamily”, [cited by applicant]
Smith, D.W., [cited by applicant]
Warden-Rothman, et al., “Sortase-Tag Expressed Protein Ligation: Combining Protein Purification and Site-Specific Bioconjugation into a Single Step”, [cited by applicant]
Witte, et al., “Site-Specific Protein Modification Using Immobilized Sortase in Batch and Continuous-Flow Systems”, [cited by applicant]
Zhao, et al., “One-Step Purification and Immobilization of Extracellularly Expressed Sortase A by Magnetic Particles to Develop a Robust and Recyclable Biocatalyst”, [cited by applicant]